T1	Premise 1197 1245	There were no unexpected serious adverse events.
T2	Premise 1246 1504	In the 684 patients with data that could be evaluated, ultrasonography of the neck was normal in 652 (95%), and the stimulated thyroglobulin level was 1.0 ng per milliliter or less in 621 of the 652 patients (95%) without detectable thyroglobulin antibodies.
T3	Premise 1505 1568	Thyroid ablation was complete in 631 of the 684 patients (92%).
T4	Premise 1569 1675	The ablation rate was equivalent between the (131)I doses and between the thyrotropin-stimulation methods.
T5	Claim 1676 1839	The use of recombinant human thyrotropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the management of low-risk thyroid cancer.
R1	Support Arg1:T4 Arg2:T5	
R2	Support Arg1:T3 Arg2:T5	
R3	Support Arg1:T2 Arg2:T5	
R4	Support Arg1:T1 Arg2:T5	
